Sophia Heinrich

Sophia Heinrich

Auto-generated profile, based on publicly available information

Sophia Heinrich

Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
LMLichun Ma
Lichun Ma
LWLimin Wang
Limin Wang
SKSubreen A. Khatib
Subreen A. Khatib
CCChing-Wen Chang
Ching-Wen Chang
SHSophia Heinrich
Sophia Heinrich
XWXin Wei Wang
Xin Wei Wang

1 December 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
LDLaurence P. Diggs
Laurence P. Diggs
BRBenjamin Ruf
Benjamin Ruf
CMChi Ma
Chi Ma
BHBernd Heinrich
Bernd Heinrich
LCLinda Cui
Linda Cui
TGTim F. Greten
Tim F. Greten

1 March 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
SHSophia Heinrich
Sophia Heinrich
ACAmanda J. Craig
Amanda J. Craig
LMLichun Ma
Lichun Ma
BHBernd Heinrich
Bernd Heinrich
TGTim F. Greten
Tim F. Greten
XWXin W. Wang
Xin W. Wang

1 January 2019 in International Journal of Biological Sciences
Verified
Journal Article
Open access
VFValerie Fako
Valerie Fako
SMSean P. Martin
Sean P. Martin
YPYotsawat Pomyen
Yotsawat Pomyen
ABAnuradha Budhu
Anuradha Budhu
JCJittiporn Chaisaingmongkol
Jittiporn Chaisaingmongkol
XWXin Wei Wang
Xin Wei Wang
Transarterial chemoembolization (TACE) is a commonly used treatment modality in hepatocellular carcinoma (HCC). The ability to identify patients who will respond to TACE represents an important clinical need, and tumor gene expression patterns may be associated with TACE response. We investigated whether tumor transcriptome is associated with TACE response in patients with HCC. We analyzed transcriptome data of treatment-naïve tumor tissues from a Chinese cohort of 191 HCC patients, including 105 patients who underwent TACE following resection with curative intent. We then developed a gene signature, TACE Navigator, which was associated with improved survival in patients that received either adjuvant or post-relapse TACE. To validate our findings, we applied our signature in a blinded manner to three independent cohorts comprising an additional 130 patients with diverse ethnic backgrounds enrolled in three different hospitals who received either adjuvant TACE or palliative TACE.

28 November 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DCDarko Castven
Darko Castven
DBDiana Becker
Diana Becker
CCCarolin Czauderna
Carolin Czauderna
DWDiana Wilhelm
Diana Wilhelm
JAJesper B Andersen
Jesper B Andersen
Jens U. MarquardtJens U. Marquardt
Jens U. Marquardt

1 September 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
LMLichun Ma
Lichun Ma
ACAmanda Craig
Amanda Craig
SHSophia Heinrich
Sophia Heinrich